Ubrelvy is not a triptan. It belongs to a different class of migraine drugs called gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists. While both triptans and Ubrelvy treat acute migraine attacks, they work through completely different biological pathways and carry different safety profiles.
How Ubrelvy Works Differently From Triptans
Triptans target serotonin receptors in the brain. Specifically, they activate 5-HT1B/1D receptors, which constricts blood vessels in and around the brain. This vasoconstriction was originally thought to be the core reason triptans relieve migraine pain, and it remains central to how they function.
Ubrelvy (generic name: ubrogepant) takes a completely different approach. During a migraine, levels of a protein called CGRP surge in the brain. CGRP binds to receptors on blood vessels and nerve cells, triggering inflammation, blood vessel dilation, and pain signaling through the trigeminal nerve, which is the main pain pathway involved in migraine. Ubrelvy blocks CGRP from reaching those receptors with extremely high precision, shutting down the cascade of inflammation and pain relay without narrowing blood vessels at all.
Why the Distinction Matters for Safety
The biggest practical difference between triptans and gepants like Ubrelvy comes down to cardiovascular risk. Because triptans constrict blood vessels, they carry contraindications for people with heart disease, a history of stroke, uncontrolled high blood pressure, or significant cardiovascular risk factors. That rules out a substantial number of migraine patients.
Ubrelvy does not cause vasoconstriction and does not carry those cardiovascular contraindications. For people who can’t safely take triptans, or who have been told by their doctor to avoid them, gepants fill a real treatment gap. Research has confirmed that effective migraine relief does not require vasoconstriction, which is part of why CGRP-targeting drugs were developed in the first place.
What Ubrelvy Is Approved For
The FDA approved Ubrelvy for the acute treatment of migraine with or without aura in adults. It is not approved for migraine prevention. You take it when a migraine starts, not on a daily schedule to reduce attack frequency.
It comes in 50 mg and 100 mg tablets. If the first dose doesn’t fully resolve your migraine, you can take a second dose at least two hours later. The maximum in a 24-hour period is 200 mg. You can take it with or without food.
How Effective Is Ubrelvy?
In pooled results from the two main phase 3 trials (ACHIEVE I and ACHIEVE II), 20.5% of people taking Ubrelvy 50 mg were completely pain-free at two hours, compared to 13% on placebo. That may sound modest as a raw number, but complete pain freedom is a high bar. The difference was statistically significant, and many additional patients experienced meaningful pain reduction short of full freedom.
The most commonly reported side effects are nausea and sleepiness, and both tend to be mild.
Ubrelvy as an Option After Triptan Failure
Not everyone responds to triptans. Some people get inadequate relief, others can’t tolerate the side effects, and others have health conditions that make triptans unsafe. Both the American Headache Society and the European Headache Federation recommend that patients who have had an inadequate response to at least two oral triptans may be appropriate candidates for gepants like Ubrelvy or for a related class called ditans. Clinical evidence shows gepants are effective even in people who didn’t respond to triptans, which makes sense given the entirely different mechanism.
If you’ve been using triptans successfully and wondering whether to switch, there’s generally no reason to change what works. But if triptans haven’t been effective for you, cause side effects you don’t want, or are off the table because of cardiovascular concerns, Ubrelvy represents a genuinely different option rather than just another version of the same drug.
Gepants vs. Triptans vs. Ditans
It helps to understand where Ubrelvy sits in the broader landscape of acute migraine treatments:
- Triptans (sumatriptan, rizatriptan, and others) activate serotonin 5-HT1B/1D receptors, cause vasoconstriction, and are contraindicated in cardiovascular disease. They remain the standard of care for most migraine patients.
- Gepants (ubrogepant/Ubrelvy, rimegepant/Nurtec) block CGRP receptors. No vasoconstriction, no cardiovascular contraindications. Some gepants are also approved for migraine prevention, though Ubrelvy is not.
- Ditans (lasmiditan/Reyvow) activate a different serotonin receptor, 5-HT1F, which does not cause vasoconstriction. They also lack cardiovascular contraindications but can cause significant drowsiness, and driving is restricted for eight hours after a dose.
All three classes are effective for acute migraine. The choice between them depends on your cardiovascular health, how you’ve responded to previous treatments, side effect tolerance, and cost considerations.